Related Experiment Videos
Comparative analysis of long-term mortality after thrombolytic therapy
1Cardiovascular Research Unit, University of Edinburgh, Scotland, United Kingdom.
The American Journal of Cardiology
|December 5, 1991
Summary
Thrombolytic therapy improves outcomes in acute myocardial infarction. One-year mortality is the best measure for comparing thrombolytic treatments, showing a significant reduction with anistreplase.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy significantly impacts acute myocardial infarction (AMI) indicators like left ventricular function and infarct size.
- Clinical indicators are insufficient for comparing thrombolytic regimens; mortality serves as the gold standard.
Purpose of the Study:
- To evaluate the efficacy of thrombolytic regimens in acute myocardial infarction.
- To determine if long-term mortality is a more reliable endpoint for comparing thrombolytic agents than short-term indicators.
Main Methods:
- Meta-analysis of previous major mortality studies.
- Pooled life table analysis of all anistreplase studies in acute myocardial infarction.
Main Results:
- No single thrombolytic agent demonstrated superiority in short-term mortality based on meta-analysis of existing studies.
- Anistreplase showed an approximate 48% odds reduction in one-year mortality in a pooled analysis.
Conclusions:
- Long-term mortality provides a more meaningful basis for comparing the efficacy of thrombolytic regimens in acute myocardial infarction.
- Anistreplase demonstrates significant long-term survival benefits in patients with acute myocardial infarction.